お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
デフォルト表紙
市場調査レポート
商品コード
968752

抗肥満薬の世界市場 - 薬剤の種類別・流通チャネル別・地域別:市場規模・シェア・将来展望・機会分析

Obesity Management Drugs Market, By Drug Type, By Distribution Channel, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

出版日: | 発行: Coherent Market Insights | ページ情報: 英文 172 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=111.74円
抗肥満薬の世界市場 - 薬剤の種類別・流通チャネル別・地域別:市場規模・シェア・将来展望・機会分析
出版日: 2020年09月29日
発行: Coherent Market Insights
ページ情報: 英文 172 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 目次
概要

現在、世界各国で不健康な生活習慣などが原因で肥満症の患者が増加しています。その動きに対応して、抗肥満薬 (減量薬) や体重管理技術の需要も拡大していくと考えられています。

当レポートでは、世界の抗肥満薬 (肥満管理薬) の市場について分析し、製品の概要や、市場の基本構造および促進・抑制要因、全体的な市場規模の見通し (金額ベース、過去4年間・今後8年間分)、薬剤の種類別・流通チャネル別・地域別の詳細動向、主要企業のプロファイル・業績・戦略計画などを調査しております。

目次

第1章 分析目的・前提条件

第2章 市場概略

  • 分析概要
    • 市場の定義と範囲
  • エグゼクティブサマリー
  • COM (Coherent Opportunity Map:市場機会マップ)

第3章 市場の力学・規制・動向の分析

  • 市場力学
    • 市場促進要因
    • 市場抑制要因
    • 市場機会
  • 影響度の分析
  • 近年の主な動き
  • 規制シナリオ
  • PEST分析
  • 新型コロナウイルス感染症 (COVID-19) の影響の分析

第4章 世界の抗肥満薬市場:薬剤の種類別

  • イントロダクション
    • 市場シェア分析
    • 対前年成長率 (YoY) の分析
    • セグメント別の動向
  • ブプロピオン・ナルトレキソン
    • イントロダクション
    • 市場規模とその予測、対前年成長率 (YoY) (金額ベース)
    • セグメント別動向
  • オルリスタット
  • ロカセリン
  • フェンテルミン・トピラマート
  • リラグルチド

第5章 世界の抗肥満薬市場:流通チャネル別

  • イントロダクション
  • 病院薬局
  • 小売薬局
  • eコマース

第6章 世界の抗肥満薬市場:地域別

  • イントロダクション
  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • フランス
    • スペイン
    • ロシア
    • 他の欧州諸国
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • ASEAN諸国
    • オーストラリア
    • 韓国
    • 他のアジア太平洋諸国
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
    • 他のラテンアメリカ諸国
  • 中東
    • GCC諸国
    • イスラエル
    • 他の中東諸国
  • アフリカ
    • 北部アフリカ
    • 中部アフリカ
    • 南部アフリカ

第7章 競合情勢

  • 企業プロファイル
    • F Hoffmann La Roche Ltd.
    • GlaxoSmithKline plc.
    • Orexigen Therapeutics, Inc.
    • Arena Pharmaceuticals, Inc.
    • VIVUS, Inc.
    • Novo Nordisk A/S
    • Eisai Co., Ltd.

第8章 付録

目次

Title:
Obesity Management Drugs Market, By Drug Type (Bupropion and Naltrexone, Orlistat, Lorcaserin, Phentermine and Topiramate, Liraglutide), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, E-commerce), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027.

Obesity is defined as excess body fat accumulation. The major factors contributing to obesity throughout the world are diseases and adoption of unhealthy life. Increasing prevalence of obesity in developed and emerging economies of the world is projected to propel the growth of the market during the forecasted period. For instance, according to reports published by the World Federation of Obesity, roughly 27.4 million children in India will be obese by 2030. This rapid increase in childhood obesity in India is expected to increase demand for weight loss and obesity management techniques during the forecast period.

Restraints of the Global Obesity Management Drugs Market

Major factors hampering the growth of the obesity management drugs market during the forecast period constitutes of lack of proper healthcare infrastructure along with improper development and implementation of clinical practice guidelines.

Key features of the study:

  • This report provides in-depth analysis of the global obesity management drugs market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2020-2027), considering 2019, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
  • It profiles leading players in the global obesity management drugs market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include F Hoffmann La Roche Ltd., GlaxoSmithKline plc., Orexigen Therapeutics, Inc., Arena Pharmaceuticals, Inc., VIVUS, Inc., Novo Nordisk A/S, and Eisai Co., Ltd.
  • Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global obesity management drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.

Detailed Segmentation

  • Global Obesity Management Drugs Market, By Drug Type:
    • Bupropion and Naltrexone
    • Orlistat
    • Lorcaserin
    • Phentermine and Topiramate
    • Liraglutide
  • Global Obesity Management Drugs Market, By Distribution Channel:
    • Hospitals Pharmacies
    • Retail Pharmacies
    • E-commerce
  • Global Obesity Management Drugs Market, By Geography:
    • North America
  • By Drug Type
    • Bupropion and Naltrexone
    • Orlistat
    • Lorcaserin
    • Phentermine and Topiramate
    • Liraglutide
  • By Distribution Channel
    • Hospitals Pharmacies
    • Retail Pharmacies
    • E-commerce
  • By Country:
    • U.S.
    • Canada
    • Europe
  • By Drug Type
    • Bupropion and Naltrexone
    • Orlistat
    • Lorcaserin
    • Phentermine and Topiramate
    • Liraglutide
  • By Distribution Channel
    • Hospitals Pharmacies
    • Retail Pharmacies
    • E-commerce
  • By Country:
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
  • By Drug Type
    • Bupropion and Naltrexone
    • Orlistat
    • Lorcaserin
    • Phentermine and Topiramate
    • Liraglutide
  • By Distribution Channel
    • Hospitals Pharmacies
    • Retail Pharmacies
    • E-commerce
  • By Country:
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
    • Latin America
  • By Drug Type
    • Bupropion and Naltrexone
    • Orlistat
    • Lorcaserin
    • Phentermine and Topiramate
    • Liraglutide
  • By Distribution Channel
    • Hospitals Pharmacies
    • Retail Pharmacies
    • E-commerce
  • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Middle East:
  • By Drug Type
    • Bupropion and Naltrexone
    • Orlistat
    • Lorcaserin
    • Phentermine and Topiramate
    • Liraglutide
  • By Distribution Channel
    • Hospitals Pharmacies
    • Retail Pharmacies
    • E-commerce
  • By Country:
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
  • By Drug Type
    • Bupropion and Naltrexone
    • Orlistat
    • Lorcaserin
    • Phentermine and Topiramate
    • Liraglutide
  • By Distribution Channel
    • Hospitals Pharmacies
    • Retail Pharmacies
    • E-commerce
  • By Country/Region:
    • Central Africa
    • South Africa
    • North Africa
  • Company Profiles
    • F Hoffmann La Roche Ltd.*
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Key Strategies
  • Recent Developments
    • GlaxoSmithKline plc.
    • Orexigen Therapeutics, Inc.
    • Arena Pharmaceuticals, Inc.
    • VIVUS, Inc.
    • Novo Nordisk A/S
    • Eisai Co., Ltd.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and Assumption

    • Research Objectives
    • Assumptions
    • Abbreviations

2. Market Purview

    • Report Description
  • Market Definition and Scope
    • Executive Summary
  • Market Snippet, By Drug Type
  • Market Snippet, By Distribution Channel
    • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

    • Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
    • Impact Analysis
    • Key Developments
    • Regulatory Scenario
    • PEST Analysis
    • COVID-19 Impact Analysis

4. Global Obesity Management Drugs Market, By Drug Type, 2019 - 2027 (US$ Mn)

    • Introduction
  • Market Share Analysis, 2019 and 2027 (%)
  • Y-o-Y Growth Analysis, 2017-2027
  • Segment Trends
    • Bupropion and Naltrexone
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Segment Trends
    • Orlistat
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Segment Trends
    • Lorcaserin
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Segment Trends
    • Phentermine and Topiramate
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Segment Trends
    • Liraglutide
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Segment Trends

5. Global Obesity Management Drugs Market, By Distribution Channel, 2019 - 2027 (US$ Mn)

    • Introduction
  • Market Share Analysis, 2019 and 2027 (%)
  • Y-o-Y Growth Analysis, 2017-2027
  • Segment Trends
    • Hospitals Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • E-commerce
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)

6. Global Obesity Management Drugs Market, By Regions, 2019 - 2027 (US$ Mn)

    • Introduction
  • Market Share Analysis, 2019 and 2027 (%)
  • Y-o-Y Growth Analysis, 2017-2027
  • Segment Trends
    • North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • U.S.
    • Canada
    • Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
    • Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • North Africa
    • Central Africa
    • South Africa

7. Competitive Landscape

    • Company Profiles
  • F Hoffmann La Roche Ltd.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • GlaxoSmithKline plc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Orexigen Therapeutics, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Arena Pharmaceuticals, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • VIVUS, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Novo Nordisk A/S
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Eisai Co., Ltd.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

8. Section

    • References
    • Research Methodology
    • About us and Sales Contact
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.